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Abstract 
Objectives 
Randomized controlled trials (RCTs) deliver robust internally valid evidence but generalizability is 
often neglected. Design features built into the ProtecT RCT of treatments for localized prostate 
cancer (PCa) provided insights into its generalizability.  
Study design and setting 
Population-based cluster-randomization created a prospective study of PSA-testing and a 
comprehensive-cohort study including groups choosing treatment or excluded from the RCT, as well 
as those randomized. Baseline information assessed selection and response during RCT conduct.  
Results 
The prospective study (82,430 men PSA-tested) represented healthy men likely to respond to a 
screening invitation. The extended comprehensive-cohort comprised 1,643 randomized, 997 
choosing treatment, and 557 excluded with advanced cancer/comorbidities.  Men choosing 
treatment were very similar to randomized men except for having more professional/managerial 
occupations. Excluded men were similar to the randomized socio-demographically but different 
clinically, representing less healthy men with more advanced PCa.  
Conclusion 
The ProtecT RCT’s design features provided data to assess the representativeness of the prospective 
cohort and generalizability of the RCT’s findings. Greater attention to collecting data at the design 
stage of pragmatic trials would better support later judgements by clinicians/policy-makers about 
the generalizability of RCT findings in clinical practice. 
Keywords: randomized; clinical trial; generalizability; external validity; prostate cancer; 
comprehensive cohort 
ProtecT Current Controlled Trials number ISRCTN20141297; ClinicalTrials.gov NCT02044172.  
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What is new? 
Key findings 
 Decisions taken when designing the ProtecT prostate cancer treatment and linked CAP screening 
RCTs enabled the collection of data to assess the representativeness of the prospective study of 
PSA-testing and generalizability of the ProtecT RCT’s findings 
 Adding the  extended comprehensive-cohort study comprising all men diagnosed with prostate 
cancer, including those who chose a treatment or were ineligible for the RCT with advanced 
cancer or comorbidities as well as those randomized in ProtecT, allowed the assessment of  the 
generalizability of the trial’s findings to patients diagnosed with prostate cancer in routine care  
What this adds to what is known 
 Aspects of the generalizability of pragmatic RCTs can be evaluated through initiatives at the 
design phase, such as assessing factors associated with participation at various stages through a 
preceding prospective study and/or collecting data from those choosing treatments or excluded 
from the trial according to eligibility criteria, although these decisions will have time and 
resource implications    
 Including an innovatively extended comprehensive-cohort study of all men diagnosed with a 
condition like prostate cancer can enable assessment of important similarities and differences 
between the randomized group and those who choose a treatment in standard practice or  with 
aspects of advanced cancer or comorbidities that preclude trial participation – providing insights 
about the RCT’s applicability to patients in routine practice 
What is the implication/what should change now 
 Greater attention should be devoted at the design stage of pragmatic RCTs to ensure that 
appropriate data are collected to support later judgements by clinicians and policy-makers about 
the generalizability of the RCT’s findings to patients in routine clinical practice 
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1. Introduction 
1.1 Pragmatic RCTs and generalizability  
Randomized controlled trials (RCTs) offer the most rigorous way to evaluate the effectiveness of 
treatments, but there are often concerns about the generalizability of findings [1-3]. A real or 
perceived lack of relevance to patients in routine care contributes to the slow or limited up-take of 
RCT evidence into practice (4,5]. RCTs remain the primary design for evaluation because random 
allocation of participants to treatment groups helps ensure against selection bias. Whether and to 
what degree an RCT’s findings can then be generalized to patients in similar or different settings or 
with different but related disease characteristics requires judgments including reflection on the 
evidence from a new study in relation to prior knowledge, statistical reasoning, biological plausibility, 
as well as interpretations of the impact of the RCT’s eligibility criteria in the context of contemporary 
clinical practice[3].  
Decisions at an RCT’s design stage can facilitate or inhibit later judgements about the generalizability 
and clinical relevance of the findings. The PRECIS-2 tool was developed to support trialists in making 
decisions to position an RCT along the continuum between explanatory efficacy approaches in ideal 
circumstances and pragmatic designs evaluating effectiveness within ‘real-world’ naturalistic 
settings[6].  There is consensus about the value of pragmatic designs in informing clinical decision-
making, but there has been considerable recent debate in this journal about how best to design such 
RCTs and the role of the PRECIS-2 tool [7-11]. In addition, a recent series has sought to provide 
theoretical and practical guidance to promote operational feasibility in pragmatic RCTs [12,13]. 
Pragmatic RCTs need to closely resemble the population and clinical practice they aim to influence to 
ensure they retain the advantages of randomization while adding the ability to produce findings that 
are generalizable. However, during the implementation of such RCTs, unanticipated challenges often 
arise in relation to recruitment, setting, equipoise, or other aspects of RCT conduct, or changes in 
clinical practice [10]. Judgments about the generalizability of an RCT require knowledge about local 
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health and care conditions, and trialists may not be best placed to do this [7]. To ensure that 
evidence-based judgments can be made, trialists need also to ensure that their design allows the 
collection of data that will later facilitate the assessment of the RCT findings’ generalizability and 
clinical relevance.   We were able to collect such data in linked RCTs in the area of prostate cancer.  
1.2 Evaluating screening and treatment for prostate cancer  
Prostate cancer (PCa) is a major cause of death for older men, and while the prostate-specific 
antigen (PSA) blood test provides the opportunity to identify the disease at a stage when it could be 
cured, screening detects many tumors that will not become clinically important and so receive 
unnecessary radical/curative treatments that cause damaging side-effects. Previously published RCTs 
focussed either on screening or treatment and have contributed valuable knowledge but not 
provided consistent findings [14-17]. In the mid/late 1990s, we designed two interlinked pragmatic 
RCTs aiming to inform policy for PCa screening and treatment practice:  
(a) CAP. The CRUK/DH (Cancer Research UK/UK Department of Health) CAP (Cluster randomised 
trial of PSA testing for PCa)  employed cluster randomisation of general practices in a Zelen 
design to create an intervention arm comprising a prospective study of men undergoing PSA-
testing and a control arm of usual NHS care without organised PSA-testing (Figure 1; baseline 
details[18]). 
(b) ProtecT.  The NIHR (National Institute for Health Research) ProtecT (Prostate testing for cancer 
and Treatment) RCT evaluated the effectiveness and cost-effectiveness of the three major 
standard treatments for clinically localized PCa diagnosed during the prospective study of PSA-
testing: radical surgery, radical external-beam radiotherapy, and active monitoring (Figure 1; 
baseline details [19]).  
These RCTs were intended to be pragmatic in design, and knowing that the primary outcomes would 
not be published until a median of 10 years’ follow-up, decisions were taken at the design stage to 
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provide data to facilitate the later evaluation of the generalizability and clinical relevance of the 
findings.  
Initially, a feasibility study was undertaken to investigate whether it was possible to recruit men from 
the community to have a PSA test and then randomize those diagnosed with clinically localized PCa 
into a treatment trial.  When this feasibility was assured [20], the CAP RCT was initiated to evaluate 
screening. CAP’s population-based cluster-design created an intervention arm comprising a 
prospective study of PSA testing within which the ProtecT RCT of treatments was embedded (Figure 
1). As recruitment to ProtecT was anticipated to be particularly challenging because of 
randomization between surgery, radiotherapy or no immediate treatment (active monitoring), an 
integrated recruitment study was undertaken [21] and a comprehensive-cohort study as in[22] to 
follow-up men who declined randomisation and chose a treatment alongside those who agreed to 
be randomized. The comprehensive-cohort was then extended to include all men diagnosed with 
PCa during the prospective study but excluded from the treatment trial because of advanced PCa or 
comorbidity – many of these men would have received one of the study treatments in usual practice 
(although they would not be eligible for all three as in the RCT). 
The collection of individual participant socio-demographic, symptomatic and clinical data at baseline 
in the prospective study of PSA testing enabled the investigation of the representativeness of the 
study population and selection factors at each stage of response and clinical eligibility.  These data 
provide information to enable judgments about the generalizability and clinical relevance of the 
findings of the recently published ProtecT primary outcomes [23,24]. This paper presents the data 
generated by the CAP/ProtecT design features, their limitations, and the insights that they can 
provide; with brief consideration of the value and practicality of such design features in pragmatic 
RCTs more generally to inform assessments of generalizability. 
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 2 Methods 
2.1 The CAP RCT 
The CAP RCT’s cluster randomization of over 900 primary-care centers in the UK created an 
intervention arm of men aged 50-69 years invited to PSA-testing and a control arm of usual NHS care 
without organized PSA-testing, followed up using routinely collected mortality data [18] (Figure 1). 
There was no evidence of differences between primary-care centres agreeing or declining to 
participate in CAP, or between men in the intervention and control practices [25]. The CAP 
intervention arm provided a population-based framework for the recruitment of men into the 
prospective study of PSA-testing and ProtecT treatment RCT.  
2.2 ProtecT prospective study of PSA-tesing 
Men aged 50-69 years registered in primary-care centres were sent one invitation to attend an 
appointment to discuss PSA-testing and the ProtecT RCT. Data available to compare responders and 
non-responders to the appointment and PSA testing were restricted to date of birth and postcode. 
While men who responded to the invitation were similar to non-responders except for being slightly 
less deprived[26], data to evaluate more detailed characteristics of non-responders were not 
available. Men attending an appointment who consented to a blood test for PSA had socio-
demographic and clinical history information collected, and completed a brief study questionnaire, 
with a more detailed questionnaire requested from men later undergoing prostate biopsies [27]. 
Comparisons were made between those participating or not at each stage through exclusion or 
choice, to provide insights about representativeness and generalizability.  
2.3 ProtecT RCT recruitment and comprehensive-cohort study 
Men diagnosed with clinically localized PCa through the PSA-testing study and meeting the 
inclusion/exclusion criteria were eligible for recruitment to the ProtecT RCT. They attended an 
appointment with a urologist for the diagnosis and basic information, and received detailed 
information about treatment options and the ProtecT RCT from a research nurse. Men were asked if 
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they would consent to random allocation of treatment. If they declined randomization, they chose a 
treatment and were included in the comprehensive-cohort (Figure 2), followed-up identically to the 
randomized.   
2.4 ProtecT extended comprehensive-cohort study 
Men diagnosed with PCa but excluded from the RCT because they had advanced cancer or were not 
eligible for all three treatments were included in the extended comprehensive-cohort  (Figure 2).  
2.5 Statistical analysis 
Socio-demographic information and data from the participant questionnaires were used to compare 
the baseline characteristics of the men at different stages of response and eligibility in the 
prospective PSA-testing study to assess response and selection (comparisons 1-5 Figure 1); and to 
compare the randomized group  with those choosing their treatment, diagnosed with advanced 
cancer, or excluded from the RCT for other reasons (comparisons 6 to 8, Figure 2).  
All statistical analyses were completed using STATA version 14.1. For continuous socio-demographic 
variables, medians and interquartile ranges were reported with Mann-Whitney tests to analyse 
differences between groups. Questionnaire data were presented with means and standard 
deviations.  Between-group comparisons were carried out to investigate whether baseline 
characteristics differed between those proceeding through PSA testing and prostate cancer diagnosis 
or excluded or choosing not to participate in the prospective cohort; and between the randomized 
and other groups in the extended comprehensive-cohort.  With ceiling effects evident at baseline, 
each continuous comparison was tested using a non-parametric Mann-Whitney test. For binary 
variables, such as previous PSA test, groups were compared using logistic regression. Ordered 
categorical variables such as occupation and cancer staging were analysed using ordinal logistic 
regression with the most-desirable/least-worse category as the base comparator. Adjustment for 
age and centre in the logistic and ordinal logistic models did not influence overall conclusions. Given 
the sample-size and large number of tests, greater attention was given to descriptive statistics rather 
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than p-values: for continuous variables, we considered with interest but caution differences greater 
than or equal to 0.5 standard deviations; likewise for categorical variables with differences that 
resulted in a risk ratio of ≤0.9.   
3 Results 
3.1 Prospective study of PSA testing and PCa diagnosis (Figure 1, Tables 1, 2 and Web 1) 
In total, 122,502 men responded to the invitation for a PSA-test, and 100,444 attended. Those who 
explicitly refused to attend (5,954) or did not attend after agreeing to do so (16,104) lived in more 
deprived areas than attenders (comparison 1, Figure 1, Table Web1).  Men who attended but 
declined the PSA-test (10,350) or were ineligible (7,665) also lived in more deprived areas than those 
who attended (comparison 2, Figure 1). 82,430 men attended and received a PSA-test (36% of those 
invited).  
At each of the stages of PSA-testing, biopsy and PCa diagnosis, the groups eligible for the RCT were 
very similar to those excluded in terms of socio-demographic characteristics (comparisons 3-5 Figure 
1). Expected clinical relationships were found, such as a positive relationship between PSA and age, 
and weak evidence for family history of the disease and diagnosis (Table 1). It was notable that those 
more likely to have a high PSA-test result or diagnosis of PCa were less likely to have previously had a 
PSA-test or urological treatment (Table 1).   
 3.2 ProtecT recruitment and comprehensive-cohort  
Overall, 3,221 men were diagnosed with PCa: 2,896 in the prospective study and 325 during the 
feasibility phase (Figure 2). 2,664 (83%) had clinically localized PCa (stage T1/T2) and were eligible for 
inclusion in the ProtecT RCT. An integrated recruitment study was undertaken to understand the 
issues underlying recruitment difficulties and provide improvements to study information and 
presentation. This increased the percentage consenting to randomization from 30% in the early 
stages to 62% at completion [21]. The comprehensive-cohort comprised:  
 
 
11 
 
 ProtecT randomized cohort: 1,643 men (62%) who consented to randomization to the ProtecT 
RCT comparing active monitoring, surgery and radiotherapy  
 ProtecT ‘treatment-choice’ cohort: 997 men (38%) who declined randomization and chose their 
treatment (273 surgery, 133 radiotherapy, 529 active monitoring, and 62 other options not 
included in the RCT (brachytherapy, high-frequency-ultrasound) 
The ‘treatment-choice’ group was very similar to the randomized in relation to clinical and socio-
demographic characteristics except that those who chose treatment were more likely to be in 
managerial/professional occupations than the randomized (53% v 42%), less deprived (11% v 15%) 
(Table 3), and more likely to have had a previous PSA test (18% v 14%). The groups were almost 
identical in responses to general health measures and symptom scores (Table 4).   
3.3 Extended comprehensive-cohort study (Figure 2, Tables 3-4) 
The following were excluded from randomization:  
 267 (8%) with advanced cancer (stage T3 or higher) 
 290 (9%) because they were considered unsuitable for the treatments for other reasons, mostly 
comorbidities 
 As expected, the 267 ‘advanced cancer’ group had much higher PSA levels, cancer stage (95% T3), 
and PCa grade (71% Gleason 7 or more) than those randomized (Table 3). They were very similar to 
the randomized group in terms of socio-demographic characteristics and health and symptom 
scores, although much less likely to have had a previous PSA test (7% v. 14%) (Table 3). The 290 
‘excluded other’ group had higher grade (37% v. 23% Gleason 7 or higher) and stage (38% v. 24% T2) 
PCa than those randomized, although not as high as the ‘advanced cancer’ men. They were similar to 
the randomized group in terms of socio-demographic characteristics and clinical history, although 
more likely to have had previous urological treatment (Table 3), and, as expected, slightly poorer 
health status with more depression and some worse urinary symptoms (Table 4).  
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4 Discussion 
A major aim of pragmatic RCTs is to produce findings that are clinically relevant and generalizable 
beyond the specific participants. The ProtecT RCT was designed to evaluate the effectiveness of 
treatments for clinically localized PCa, and was embedded in the intervention arm of the CAP RCT 
evaluating population screening. The ProtecT RCT was designed in the late 1990s, more than 15 
years before the results were published [23,24], aiming to be pragmatic and with design features 
that provided opportunities to collect data that can now be used to produce insights into the 
representativeness of the PSA-tested cohort in relation to the general population of men aged 50-69 
years, and the generalizability of the ProtecT treatment RCT findings to patients diagnosed with PCa 
in clinical practice. 
The CAP cluster-randomization of primary-care practices created comparable intervention and 
control arms and so men invited to the prospective study of PSA-testing were representative of the 
population of men aged 50-69 years [18]. However, the Zelen design then prevented access to data 
from potential participants who did not respond to the invitation to PSA-testing or would have been 
excluded with serious comorbidities by primary-care physicians. Those who attended for PSA-testing 
were probably representative of healthy men aged 50-69 years likely to respond to screening, rather 
than all men of the same age.  While this would not seriously affect the generalizability of the 
ProtecT RCT to men fit for radical treatments, it remains a limitation in relation to the wider range of 
men diagnosed with PCa in routine practice. Extending the comprehensive cohort enabled follow-up 
of some less fit men and those with more advanced disease.  
The prospective study of PSA testing served as a recruitment framework for the ProtecT treatment 
RCT, and baseline data collected during testing and PCa diagnosis allowed the exploration of 
response and clinical factors that might affect the generalizability of the RCT findings.  Very few 
differences were evident between eligible and ineligible groups (other than expected clinical factors), 
although men who declined diagnostic tests were slightly more materially deprived than consenters. 
 
 
13 
 
Similarly, in the comprehensive-cohort, men who chose treatments (‘treatment-choice’ group) were 
more likely to be in professional occupations and less materially deprived than those agreeing to 
randomization, but were otherwise almost identical.  In the extended comprehensive-cohort, socio-
demographic characteristics were very similar between the randomized and ‘advanced cancer’ or 
‘excluded-other’ groups, but the groups were different clinically, representing a wider range of 
patients who would receive the RCT treatments or other approaches such as hormone therapy in 
routine practice.   
This study had several strengths and limitations. Many RCTs fail to include sufficient numbers of 
older people, women, ethnic minorities and those with greater deprivation [28]. The prospective 
study recruited in areas outside London with very small numbers from ethnic minorities, and 
participation rates were proportionate to those populations [27]. The lack of diversity is a limitation 
in terms of wider representativeness, although treatment outcomes have recently been shown to be 
similar between ethnic groups in the US [29]. More deprived individuals were less likely to respond 
at each stage in the prospective study, suggesting that new approaches to encourage participation of 
these groups are required.  
Recruitment is challenging for many RCTs [30]. It has been suggested that pragmatic RCTs requiring 
‘usual care’ comparators should be embedded in prospective cohort studies in which participants 
have already consented to take part: ’cohort multiple RCTs’ [31]. This design could allow many RCTs 
to be conducted, although only among those agreeing to multiple study participation, and thus not 
addressing important issues of response bias.  Other design solutions to recruitment difficulties 
include ‘preference’ designs where intervention preferences are elicited and those without strong 
views are randomized[32], or comprehensive-cohorts where those who decline randomization and 
choose a treatment are also followed-up alongside those randomized [22]. Each design raises ethical 
and practical issues, but successful examples [33] indicate they can produce considerable data to 
assess generalizability, and so should be further explored practically and methodologically. 
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Baseline characteristics were well balanced between the arms in both CAP[18]  and ProtecT [19] 
RCTs, with high levels of retention and follow-up, indicative of good internal validity and the 
robustness of the findings. Another strength of ProtecT was the high level of randomization of 
eligible participants – at 62%, much higher than the similar PIVOT (14.6%) [17] and most other 
cancer RCTs [34].  This was achieved by the integration of qualitative research to optimize 
recruitment and informed consent[21,35] and dedicated staff training[36]. Men who declined 
randomization were very similar to the randomized in almost every respect, except for having more 
professional occupations and lower deprivation. These patients, choosing treatments as they would 
in usual care, along with the extended comprehensive-cohort of patients excluded from the RCT but 
likely to be encountered in routine care, will provide many opportunities for analysis of clinical 
relevance and generalizability in due course.  
It will be important to assess the impact of changes in PCa diagnosis since recruitment such as the 
introduction of multi-parametric MRI [37]. There have also been changes in treatment techniques, 
including robot-assisted surgery and developments in radiotherapy and methods of active 
surveillance, although recent evaluations of short- and medium-term oncological and patient-
reported functional outcomes - expected to be better with newer techniques - have produced 
remarkably similar results to ProtecT [38-40], suggesting ProtecT’s continuing clinical relevance. A 
recent English national audit showed the majority of patients receiving surgery in 2014-2015 had a 
much higher grade and stage profile than those in ProtecT [41] – but the audit included men 
diagnosed clinically with symptoms as well from low background PSA-testing  (around 6% p.a. in the 
UK [42]).  
The small number of men with high-risk PCa randomized in ProtecT is a limitation, but some of these 
were included in the extended comprehensive-cohort ‘advanced’ and ‘excluded’, followed-up 
observationally [43]. The prospective study suggested that other high-risk men had earlier moved 
into routine care through previous PSA-testing or urological treatment (Table 1) and others would be 
among those who declined the PSA-test invitation at the outset. The ProtecT findings are likely to be 
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most relevant for men with low and intermediate risk PCa and fit for treatment, who represent a 
large proportion of cases diagnosed in the UK, and even higher proportions in many parts of Europe 
and North America where higher levels of PSA testing occur.  
The PRECIS-2 tool provides support for trialists to discuss intentions to be more or less pragmatic and 
be clearer about the influence of design choices on applicability [6] but some have suggested that, 
while useful, this is only the first stage, and that operational challenges (and solutions) during trial 
conduct can have a greater impact on a trial’s generalizability[10,13]. The ProtecT and CAP RCTs 
were designed long before these tools/guidelines were available. While they would undoubtedly 
have been helpful, we would suggest that alongside these tools/guidelines at the design stage, 
trialists should also ensure that they collect robust data that will later permit evidence-based insights 
into generalizability.  
Such design-decisions will inevitably have an impact on resources, but adding comprehensive-cohort 
studies and extending them as in this study are likely to provide considerable added value at 
relatively little cost. A real or perceived lack of relevance to patients in routine care continues to 
contribute to the slow or limited up-take of RCT evidence into practice [4,5]. Pragmatic RCTs need to 
provide applicable evidence, and initiatives such as those reported in this study are needed to 
provide evidence to increase clinicians’ and policy-makers’ confidence in the generalizability of trial 
findings.   
5. Conclusions 
Even the most pragmatic RCTs have limitations in terms of generalizability, but it is usually difficult to 
determine whether these relate to decisions made at the time of design, during trial conduct, or 
because of changes in clinical practice.  While some of these issues may be mitigated through the 
use of tools such as PRECIS-2 or guidelines when making design decisions, the scale and scope of 
most pragmatic RCTs means that unanticipated limitations will arise before outcomes are published. 
The assessment of the generalizability of an RCT’s findings requires wide-ranging judgements about 
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the design and conduct of the RCT, the characteristics of its participants, and the relevance of the 
interventions and outcomes in the context of contemporary clinical practice. The embedding of the 
ProtecT RCT in a prospective study and with an extended comprehensive-cohort enabled data to be 
collected to support evidence-based judgements by clinicians and policy-makers about the 
generalizability of the randomized outcomes to patients in routine practice.  With increasing 
willingness to undertake pragmatic RCTs to inform policy and practice, and tools to assist design and 
implementation, attention now also needs to be devoted to ensuring the collection of data that will 
provide insights into the generalizability of the randomized findings and facilitate the application of 
evidence more easily into clinical practice.  
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Figure 1 CAP trial framework, and comparison points in the ProtecT prospective study of PSA testing 
and diagnosis 
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Figure 2 ProtecT RCT extended comprehensive-cohort study and comparison points  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3,221 diagnosed with prostate cancer  
(2,896 main trial prospective study,         
325 feasibility study) 
2,664 localized prostate cancer  
Eligible for inclusion in trial  
ProtecT treatment trial  
1,643 randomised  
Excluded from ProtecT trial 
267 with advanced prostate cancer (‘advanced’ group) 
290 with other criteria (‘excluded other’ group) 
997 chose treatment (‘preference’ group) 
[24 randomised in discontinued two-arm study] 
 
Comparison 
6 
7 
8 
 
 
25 
 
Table 1. Baseline differences in socio-demographic and clinical factors for participants in the ProtecT prospective study of PSA testing and cancer diagnosis 
 Had a PSA test£ 
n=82,430 
PSA<3 
n=73,538 
PSA≥20 
n=280 
Trial eligible PSA (3≤PSA<20) 
n=8,566 
  All eligible 
n=8,566 
Declined biopsy 
n=1,152 
Biopsy 
n=7,414 
Received biopsy 
n=7,414 
Negative 
n=4,518 
Positive 
n=2,896 
Age [n] 
    Median age (IQR) 
[73,538] 
58.0 (8.0)* 
[280] 
64.0 (7.0) 
[8,566] 
62.0 (8.0)* 
[1,152] 
62.0 (8.0) 
[7,414] 
62.0 (8.0) 
[4,518] 
61.0 (8.0) 
[2,896] 
62.0 (8.0) 
    P value p<0.001a p<0.001b  p<0.001c  p<0.001d  
Ethnicity 
   White n(%) 
   Other n(%) 
 
71,948 (98%) 
1127 (2%) 
 
265 (96%) 
10 (4%) 
 
8,377 (99%) 
108 (1%) 
 
1,113 (98%) 
23 (2%) 
 
7,264 (99%) 
85 (1%) 
 
4,425 (99%) 
52 (1%) 
 
2,839 (99%) 
33 (1%) 
    P value p=0.055a p=0.001b  p=0.017c  p=0.961d  
Marital Status 
   Married/living as married n(%) 
   Other (e.g. divorced) n(%) 
 
61,507 (84%) 
11,641 (16%) 
 
226 (82%) 
49 (18%) 
 
7,091 (83%) 
1,410 (17%) 
 
941 (83%) 
198 (17%) 
 
6,150 (84%) 
1,212 (16%) 
 
3,730 (83%) 
755 (17%) 
 
2,420 (84%) 
457 (16%) 
    P value p=0.110a p=0.589b  p=0.437c  p=0.284d  
Occupation present or last paid 
   Managerial n(%) 
   Intermediate n(%) 
   Working n(%) 
 
9,948 (44%) 
3,886 (17%) 
8,717 (39%) 
 
106 (41%)* 
44 (17%) 
110 (42%)* 
 
3,783 (46%)* 
1,351 (16%) 
3,067 (37%)* 
 
499 (49%) 
155 (15%) 
355 (35%) 
 
3,284 (46%) 
1,196 (17%) 
2,712 (38%) 
 
2,024 (47%) 
734 (17%) 
1,588 (37%) 
 
1,260 (44%) 
462 (16%) 
1,124 (39%) 
    P value p=0.005a p=0.073b  p=0.036c  p=0.018d  
Cancer/treatment history 
    Previous PSA test 
    P value 
    Previous urinary/prostate treatment 
    P value 
    Family history of cancer (prostate only) 
    P value 
    Family history of cancer (all) 
    P value 
 
9,229 (13%)* 
p<0.001a 
5,980 (8%)* 
p<0.001a 
3,748 (6%)* 
p<0.001a 
36,541 (53%) 
p<0.001a 
 
17 (6%)* 
p<0.001b 
24 (9%)* 
p=0.058b 
17 (7%) 
p=0.765b 
144 (57%) 
p=0.567b 
 
1,594 (19%)* 
 
1,069 (13%)* 
 
554 (7%)* 
 
4,445 (56%) 
 
 
279 (25%)* 
p<0.001c 
171 (15%)* 
p=0.007c 
70 (7%) 
p=0.652c 
569 (54%) 
p=0.177c 
 
1,315 (18%)* 
 
898 (12%)* 
 
484 (7%) 
 
3,876 (56%) 
 
 
892 (20%)* 
p<0.001d 
644 (14%)* 
p<0.001d 
264 (7%)* 
p=0.002d 
2,320 (55%) 
p=0.030d 
 
423 (15%)* 
 
254 (9%)* 
 
220 (9%)* 
 
1556 (57%) 
 
Deprivation score [overall n] 
    Living in an area of deprivation$ n(%) 
    P value 
[73,027] 
10016 (14%) 
p=0.044a 
[279] 
34 (12%) 
p=0.718b 
[8,488] 
1097 (13%) 
 
[1,143] 
152 (13%) 
p=0.685c 
[7,345] 
945 (13%) 
 
[4,484] 
538 (12%)* 
p=0.005d 
[2,861] 
407 (14%)* 
 
PSA level at baseline [n] 
    Median PSA level (IQR) 
    P value 
[73,538] 
0.9 (0.9)* 
 
[280] 
32.1 (29.0)* 
 
[8,566] 
4.2 (2.5)* 
[1,152] 
3.9 (2.0) 
p<0.001c 
[7,414] 
4.3 (2.5) 
[4,518] 
4.1 (2.0) 
p<0.001d 
[2,896] 
4.8 (3.4) 
*Differences of interest when using the ≥0.5sds cut off for continuous outcomes or the ≤0.9RR cut off for categorical outcomes 
£46 men had no result 
aComparison between PSA<3 and eligible PSA 
bComparison between PSA≥20 and eligible PSA 
cComparison between those who had a biopsy and those who did not 
dComparison between those with a negative biopsy result and those with a positive biopsy result 
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Table 2. Patient-reported general health and symptomatic measures: baseline differences for participants in the ProtecT prospective study of PSA-
testing 
 Had a PSA test£ 
n=82,430 
PSA<3 
n=73,538 
PSA≥20 
n=280 
 Trial eligible PSA (3≤PSA<20) 
n=8,566 
  All eligible 
n=8,566 
Declined biopsy 
n=1,152 
Biopsy 
n=7,414 
Received biopsy 
n=7,414 
Negative 
n=4,518 
Positive 
n=2,896 
SF-12 [minimum n] 
    Mean physical score(sd) 
     P value 
     Mean mental score(sd) 
     P value 
[n=60,146] 
49.6 (9.0) 
p=0.029a 
53.2 (8.4) 
p<0.001a 
[n=225] 
49.5 (9.2) 
p=0.764b 
54.3 (7.8) 
p=0.205b 
[n=6,925] 
49.4 (9.0) 
 
53.8 (7.8) 
[n=902] 
48.6 (9.6) 
p=0.028c 
53.9 (8.1) 
p=0.219c 
[n=6,023] 
49.5 (8.9) 
 
53.8 (7.8) 
[n=3,710] 
49.7 (8.8) 
p=0.070d 
53.8 (7.8) 
p=0.715d 
[n=2,313] 
49.3 (9.0) 
 
53.8 (7.8) 
HADS [minimum n] 
    Anxiety case (≥8) n(%) 
    P value 
    Depression case (≥8) n(%) 
    P value 
    Mean anxiety score (sd) 
    P value 
    Mean depression score (sd) 
    P value 
[n=60,917] 
13,882 (23%)* 
p<0.001a 
4,905 (8%)* 
p=0.002a 
5.2 (3.5) 
p<0.001a 
3.1 (2.8) 
p=0.012a 
[n=238] 
46 (19%) 
p=0.920b 
13 (5%)* 
p=0.356b 
4.5 (3.5) 
p=0.040b 
3.0 (2.7) 
p=0.912b 
[n=7,241] 
1,413 (20%)* 
 
508 (7%)* 
 
4.9 (3.4) 
 
3.0 (2.7) 
[n=960] 
168 (17%)* 
p=0.086c 
80 (8%)* 
p=0.087c 
4.7 (3.5) 
p=0.026c 
3.0 (3.0) 
p=0.299c 
[n=6,281] 
1245 (20%)* 
 
428 (7%)* 
 
4.9 (3.3) 
 
3.0 (2.6) 
 
[n=3,818] 
749 (20%) 
p=0.613d 
244 (6%)* 
p=0.092d 
4.9 (3.3) 
p=0.420d 
2.9 (2.6) 
p=0.076d 
[n=2,459] 
496 (20%) 
 
184 (7%)* 
 
5.0 (3.4) 
 
3.1 (2.7) 
 
EQ5D [n] 
    Mean EQ5D score 
    P value 
[n=66,332] 
0.9 (0.2) 
p=0.040a 
[n=257] 
0.9 (0.2) 
p=0.854b 
[n=7,744] 
0.9 (0.2) 
[n=1,020] 
0.9 (0.2) 
p=0.499c 
[n=6,724] 
0.9 (0.2) 
[n=4,076] 
0.9 (0.2) 
p=0.003d 
[n=2,648] 
0.9 (0.2) 
ICSmaleSF – symptoms [minimum n] 
    Delay before urinating n(%) 
    P value 
    Rush to the toilet n(%) 
    P value 
    Leak before reaching the toilet n(%) 
    P value 
    Frequency (≤3 hours per void) n(%) 
    P value 
    Nocturia n(%) 
    P value 
    Do urinary symptoms interfere with life? n(%)     
    P value 
[min n=67,084] 
29642 (44%)* 
p<0.001a 
30586 (45%)* 
p<0.001a 
13932 (21%)* 
p<0.001a 
43699 (65%) 
p<0.001a 
45310 (67%)* 
p<0.001a 
13466 (20%)* 
p<0.001a 
[min n=258] 
136 (52%) 
p=0.340b 
135 (51%)* 
p=0.051b 
82 (31%) 
p=0.323b 
171 (66%) 
p=0.238b 
183 (70%) 
p=0.059b 
60 (23%)* 
p=0.037b 
[min n=7,883] 
4340 (55%)* 
 
4549 (57%)* 
 
2246 (28%)* 
 
5496 (70%) 
 
5915 (75%)* 
 
2272 (29%)* 
[min n=1,028] 
522 (50%) 
p=0.003c 
554 (53%) 
p=0.003c 
279 (27%) 
p=0.225c 
686 (66%) 
p=0.015c 
756 (74%) 
p=0.245c 
270 (26%)* 
p=0.032c 
[min n=6,851] 
3818 (55%) 
 
3995 (58%) 
 
1967 (29%) 
 
4810 (70%) 
 
5159 (75%) 
 
2002 (29%)* 
[min n=4,173] 
2435 (58%)* 
p<0.001d 
2546 (60%)* 
p<0.001d 
1298 (31%)* 
p<0.001d 
2994 (72%) 
p=0.001d 
3167 (76%) 
p=0.196d 
1355 (32%)* 
p<0.001d 
[min n=2,678] 
1,383 (51%)* 
 
1,449 (54%)* 
 
669 (25%)* 
 
1,816 (68%) 
 
1,992 (74%) 
 
647 (24%)* 
*Differences of interest when using the ≥0.5sds cut off for continuous outcomes or the ≤0.9RR cut off for categorical outcomes 
£46 men had no result.   acomparison between PSA<3 and eligible PSA.    bcomparison between PSA≥20 and eligible PSA 
ccomparison between those who had a biopsy and those who did not.  dcomparison between those with a negative biopsy result and those with a positive biopsy result
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Table 3. Baseline differences in socio-demographic and clinical factors for those participating in the ProtecT 
RCT extended comprehensive-cohort study 
*Differences of interest when using the ≥0.5sds cut off for continuous outcomes or the ≤0.9RR cut off for categorical outcomes 
acomparison between randomised and advanced men 
bcomparison between randomised and excluded men 
ccomparison between randomised and preference men 
~includes 18 “T1/T2” in the advanced or excluded other group; ^includes 2 “T3/4” in the advanced or excluded other group 
#Defined as ‘low’ if T1 & G≤6 & PSA<10, ‘high’ if G≥8, ‘intermediate’ for all other combinations of stage, grade and PSA.   
 Randomised 
n=1643 
Advanced 
n=267 
Excluded (other) 
n=290 
Choosing 
treatment 
n=997 
Age [n] 
    Median age (IQR) 
[n=1643] 
62.0 (9.0) 
[n=267] 
63.0 (8.0) 
[n=290] 
63.0 (8.0) 
[n=997] 
62.0 (7.0) 
    P value  p=0.001a p<0.001b p=0.604c 
Ethnicity 
   White n(%) 
   Other n(%) 
 
1606 (99%) 
22 (1%) 
 
259 (99%) 
3 (1%) 
 
283 (99%) 
3 (1%) 
 
984 (99%) 
9 (1%) 
    P value  p=0.786a p=0.679b p=0.310c 
Marital Status 
   Married/living as married n(%) 
   Other (e.g. divorced) n(%) 
 
1375 (84%) 
257 (16%) 
 
231 (88%) 
31 (12%) 
 
232 (81%) 
56 (19%) 
 
841 (85%) 
151 (15%) 
    P value  p=0.103a p=0.118b p=0.719c 
Occupation present or last paid 
   Managerial n(%) 
   Intermediate n(%) 
   Working n(%) 
 
684 (42%)* 
259 (16%)* 
678 (42%)* 
 
107 (42%) 
45 (18%) 
104 (41%) 
 
121 (44%) 
46 (17%) 
111 (40%) 
 
516 (53%)* 
157 (16%)* 
307 (31%)* 
    P value  p=0.898a p=0.589b p<0.001c 
Cancer/treatment history 
    Previous PSA test 
    P value 
    Previous urinary/prostate treatment 
    P value 
    Family history of cancer (prostate only) 
    P value 
    Family history of cancer (all) 
    P value 
 
227 (14%)* 
 
142 (9%)* 
 
119 (8%)* 
 
897 (58%) 
 
19 (7%)* 
p=0.004a 
26 (10%)* 
p=0.510a 
19 (9%)* 
p=0.829a 
131 (55%) 
p=0.388a 
 
37 (13%) 
p=0.720b 
36 (13%)* 
p=0.040b 
21 (8%) 
p=0.926b 
144 (54%) 
p=0.235b 
 
175 (18%)* 
p=0.012c 
82 (8%)* 
p=0.694c 
83 (9%)* 
p=0.271c 
543 (58%) 
p=0.885c 
Deprivation score [n] 
Living in an area of deprivation$ n(%) 
    P value 
[n=1,624] 
239 (15%)* 
[n=262] 
39 (15%) 
p=0.943a 
[n=285] 
44 (15%) 
p=0.752b 
[n=977] 
111 (11%)* 
p=0.015c 
PSA level [minimum n] 
    Median baseline PSA level (IQR) 
    P value 
    Median biopsy PSA level (IQR) 
    P value 
[n=1631] 
4.6 (3.1)* 
 
4.8 (3.4)* 
[n=167] 
8.5 (8.0)* 
p<0.001a 
9.1 (8.8)* 
p<0.001a 
[n=198] 
5.2 (4.8) 
p=0.002b 
5.9 (4.8) 
p<0.001b 
[n=876] 
4.8 (3.1) 
p=0.455c 
4.8 (3.3) 
p=0.714c 
Gleason score 
    6 
    7 
    8-10 
    P value 
 
1266 (77%)* 
339 (21%)* 
37 (2%)* 
 
75 (28%)* 
140 (52%)* 
52 (19%)* 
p<0.001a 
 
181 (63%)* 
86 (30%)* 
19 (7%)* 
p<0.001b 
 
755 (76%) 
218 (22%) 
24 (2%) 
p=0.419c 
Cancer staging 
    T1~ 
    T2 
    T3^ 
    T4+ 
    P value 
 
1249 (76%)* 
394 (24%)* 
0 (0%)* 
0 (0%)* 
 
5 (2%)* 
3 (1%)* 
250 (95%)* 
4 (2%)* 
p<0.001a 
 
172 (61%)* 
106 (38%)* 
3 (1%)* 
0 (0%)* 
p<0.001b 
 
758 (76%) 
239 (24%) 
0 (0%) 
0 (0%) 
p=0.996c 
Risk categorisation# 
    Low 
    Intermediate 
    High 
    P value 
 
951 (58%) 
654 (40%) 
37 (2%) 
 
 
0 (0%) 
215 (81%) 
52 (19%) 
p<0.001a 
 
110 (38%) 
159 (55%) 
19 (7%) 
p<0.001b 
 
559 (56%) 
414 (42%) 
24 (2%) 
p=0.350c 
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Table 4. Patient-reported general health and symptomatic measures: baseline differences for those 
participating in the ProtecT RCT extended comprehensive-cohort study 
 
 Randomised 
n=1643 
Advanced 
n=267 
Excluded (other) 
n=290 
Choosing 
treatment 
n=997 
SF-12 [n] 
    Mean physical score(sd) 
     P value 
     Mean mental score(sd) 
     P value 
[min n=1260] 
51.2 (7.9) 
 
53.9 (7.5) 
 
[min n=172] 
50.0 (8.7) 
p=0.142a 
53.4 (8.4) 
p=0.982a 
[min n=190] 
47.6 (10.8) 
p<0.001b 
53.4 (8.9) 
p=0.875b 
[min n=778] 
51.3 (7.9) 
p=0.464c 
53.5 (8.2) 
p=0.974c 
HADS [n] 
    Anxiety case (≥8) n(%) 
    P value 
    Depression case (≥8) n(%) 
    P value 
    Mean anxiety score (sd) 
    P value 
    Mean depression score (sd) 
    P value 
[min n=1399] 
278 (20%) 
 
80 (6%)* 
 
4.9 (3.5) 
 
2.5 (2.5) 
[min n=201] 
47 (23%) 
p=0.317a 
12 (6%) 
p=0.886a 
5.2 (3.8) 
p=0.328a 
2.6 (2.8) 
p=0.844a 
[min n=228] 
51 (22%) 
p=0.373b 
21 (9%)* 
p=0.045b 
5.1 (3.8) 
p=0.531b 
3.2(3.1) 
p=0.001b 
[min n=853] 
180 (21%) 
p=0.504c 
44 (5%)* 
p=0.572c 
4.9 (3.5) 
p=0.933c 
2.5 (2.6) 
p=0.886c 
EQ5D [n] 
    Mean EQ5D score 
    P value 
n=1413 
0.9 (0.2)* 
 
n=206 
0.9 (0.2) 
p=0.022a 
n=224 
0.8 (0.2)* 
p<0.001b 
n=854 
0.9 (0.2) 
p=0.260c 
ICSmaleSF – symptoms [minimum n] 
    Delay before urinating n(%) 
    P value 
    Rush to the toilet n(%) 
    P value 
    Leak before reaching the toilet n(%) 
    P value 
    Frequency (≤2 hours per void) n(%) 
    P value 
    Nocturia (>1 per night) n(%) 
    P value 
    Do urinary symptoms interfere with life? n(%)     
    P value 
[min n=1410] 
725 (51%) 
 
844 (59%) 
 
407 (29%)* 
 
460 (33%) 
 
312 (22%)* 
 
367 (26%) 
[min n=208] 
101 (48%) 
p=0.388a 
137 (65%) 
p=0.098a 
72 (34%)* 
p=0.081a 
66 (32%) 
p=0.797a 
63 (30%)* 
p=0.010a 
58 (28%) 
p=0.531a 
[min n=230] 
130 (56%) 
p=0.160b 
149 (64%) 
p=0.199b 
81 (35%)* 
p=0.060b 
72 (31%) 
p=0.632b 
65 (28%)* 
p=0.034b 
66 (28%) 
p=0.401b 
[min n=856] 
422 (49%) 
p=0.387c 
502 (58%) 
p=0.596c 
206 (24%)* 
p=0.015c 
245 (30%) 
p=0.143c 
166 (19%)* 
p=0.147c 
211 (24%) 
p=0.489c 
ICSmaleSF scales [minimum n] 
    Mean ICSmaleVS (voiding scale) 
    P value 
    Mean ICSmaleIS (incontinence scale) 
    P value 
[min n=1413] 
3.3 (3.0) 
 
1.8 (1.9) 
[min n=207] 
3.2 (3.1) 
p=0.549a 
1.9 (1.8) 
p=0.668a 
[min n=231] 
3.8 (3.6) 
p=0.157b 
2.2 (2.2) 
p=0.074b 
[min n=854] 
3.3 (3.3) 
p=0.310c 
1.6 (1.7) 
p=0.087c 
ICIQ [n] 
     Mean ICIQ (sd) 
     P value 
     ICIQ QoL impact: none 
     ICIQ QoL impact: moderate 
     ICIQ QoL impact: high 
     P value 
[n=1244] 
1.3 (2.3) 
 
1174(93%) 
81(6%) 
4(<1%) 
 
[n=174] 
1.3 (2.2) 
p=0.817a 
168(94%) 
11(6%) 
0 (0%) 
p=0.754a 
[n=202] 
1.6 (2.6)  
p=0.093b 
183(89%) 
22(11%) 
0 (0%) 
p=0.046b 
[n=757] 
1.0 (2.1) 
p=0.017c 
725(95%) 
39(5%) 
1(<1%) 
p=0.167c 
EPIC urinary [minimum n] 
   Urinary summary 
    P value 
    Urinary function 
    P value 
    Urinary bother 
    P value 
    Incontinence 
    P value 
    Irritative/Obstructive 
    P value 
[min n=745] 
92.7 (9.1) 
 
95.1 (8.4) 
 
91.0 (11.7) 
 
93.0 (11.3) 
 
93.0 (9.2) 
[min n=112] 
93.3 (8.1) 
p=0.619a 
95.7 (6.7) 
p=0.826a 
91.3 (11.6) 
p=0.758a 
93.8 (9.6) 
p=0.782a 
93.5 (8.4) 
p=0.633a 
[min n=124] 
91.3 (10.5) 
p=0.163b 
94.4 (8.7) 
p=0.339b 
89.2 (13.6) 
p=0.122b 
91.3 (12.7) 
p=0.128b 
91.8 (10.4) 
p=0.186b 
[min n=503] 
93.6 (8.2) 
p=0.205c 
96.3 (7.0) 
p=0.006c 
91.6 (10.6) 
p=0.987c 
94.7 (9.8) 
p=0.012c 
93.3 (8.4) 
p=0.982c 
EPIC bowel [minimum n] 
   Bowel summary 
    P value 
    Bowel function 
    P value 
    Bowel bother 
    P value 
[min n=748] 
93.6 (8.4) 
 
92.0 (8.8) 
 
95.1 (10.0) 
[min n=113] 
92.8 (8.4) 
p=0.141a 
91.5 (8.2) 
p=0.335a 
93.9 (11.1) 
p=0.122a 
[min n=126] 
92.0 (9.9) 
p=0.024b 
90.5 (9.2) 
p=0.065b 
93.0 (14.1) 
p=0.110b 
[min n=509] 
94.0 (7.2) 
p=0.843c 
92.4 (7.9) 
p=0.436c 
95.6 (8.5) 
p=0.958c 
 
*Differences of interest when using the ≥0.5sds cut off for continuous outcomes or the ≤0.9RR cut off for categorical outcomes 
acomparison between randomised and advanced men 
bcomparison between randomised and excluded men 
ccomparison between randomised and preference men 
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Web appendix 
 
Table Web1. Baseline differences in socio-demographic factors for those responding to the invitation to the ProtecT prospective study of PSA testing 
 
 Responded to invitation 
n=122,502 
Did not-attend 
n=16,104 
Refused to attend 
n=5,954 
Attended clinic 
n=100,444 
  All attenders 
n=100,444 
Ineligible 
n=7,664 
Declined 
n=10,350 
Had a PSA test 
n=82,430 
Age [n] 
    Median age (IQR) 
[n=15,541] 
57.0 (9.0) 
[n=5,801] 
59.0 (9.0) 
[n=100,407] 
58.0 (9.0) 
 
[n=7,632] 
61.0 (9.0) 
p<0.001c  
[n=10,345] 
59.0 (10.0) 
p<0.001d 
[n=82,430] 
58.0 (9.0) 
    P value p<0.001a p<0.001b 
Deprivation score [overall n] 
   English IMD Median (IQR) 
    P value 
   Welsh IMD Median (IQR) 
    P value 
[n=15,533] 
19.2 (25.1) 
p<0.001a 
18.6 (23.9) 
p<0.001a 
[n=5,738] 
16.7 (20.7) 
p<0.001b 
17.4 (21.3) 
p<0.001b 
[n=99,435] 
15.2 (18.3) 
 
13.5 (18.9) 
[n=7,492] 
20.1 (24.8) 
p<0.001c 
18.7 (23.1) 
p<0.001c 
[n=10,103]  
17.9 (21.8) 
p<0.001d 
17.9 (19.0) 
p<0.001d  
[n=81,840] 
14.5 (17.1) 
 
13.2 (17.6) 
   Scottish IMD Median (IQR) 12.3 (19.0) 9.5 (17.6) 7.8 (12.9) 9.0 (16.7) 9.6 (15.7) 7.5 (12.6) 
    P value p<0.001a p=0.001b  p<0.001c p<0.001d  
   Living in an area of deprivation 3889 (33%)* 1089 (23%)* 15035 (18%)* 1832 (32%)* 2051 (25%)* 11152 (16%)* 
    P value p<0.001a p<0.001b  p<0.001c p<0.001d  
 
*Differences of interest when using the ≥0.5sds cut off for continuous outcomes or the ≤0.9RR cut off for categorical outcomes 
aComparison between non-attenders and attenders 
bComparison between those who refused invitation and those who attended 
cComparison between those who were ineligible and those who had a PSA test 
dComparison between those who declined and those who had a PSA test 
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